A. Sami Saribas
Consultant / Adviseur bij Ben Franklin Technology Partners /Ventures/
Profiel
Prior to joining Ben Franklin as an Advisor, Dr. Saribas was a Senior Scientist at Tetralogic Pharmaceuticals, Neose Technologies.
He was a Research Biochemist at University of Michigan Medical School.
Dr. Saribas earned a BS in Chemical Engineering from Yildiz Teknik Universitesi in 1982.
He earned an MS in Biochemistry from University of Missouri-Columbia in 1988.
Dr. Saribas earned a PhD in Chemistry and Biochemistry from the University of Akron in 1992.
He earned his Postdoc in Biology from University of Pennsylvania in 1997.
Actieve functies van A. Sami Saribas
| Bedrijven | Functie | Begin |
|---|---|---|
Ben Franklin Technology Partners /Ventures/
 Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania. | Consultant / Adviseur | - |
Eerdere bekende functies van A. Sami Saribas
| Bedrijven | Functie | Einde |
|---|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Corporate Officer/Principal | - |
| Michigan Medicine | Corporate Officer/Principal | - |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Corporate Officer/Principal | - |
Opleiding van A. Sami Saribas
| University of Missouri | Graduate Degree |
| University of Akron | Doctorate Degree |
| University of Pennsylvania | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| TETRALOGIC PHARMACEUTICALS CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Ben Franklin Technology Partners /Ventures/
Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
